In summary, current clinical and preclinical evidence supports the antidepressant properties of acetyl-L-carnitine, particularly in populations with treatment-resistant depression, and cognitive impairment in mood disturbances
It may also create other problems, especially for patients who use GLP-1 medication for diabetes management, appetite, or significant weight-related health concerns
Riss, T., Niles, A., Moravec, R., Karassina, N
P = .03) Quality of Life (QoL) Physical QoL (SF-36v2): 3.75 points (95% CI: 1.525.98
The US GDP could grow by an extra 1% if 60 million Americans took GLP-1 drugs by 2028, Jan Hatzius, the chief economist at Goldman Sachs, wrote